Phosphate binders: new products and challenges (Q36522027)

14 August 2017

1 reference

title

Phosphate binders: new products and challenges (English)

1 reference

14 August 2017

Geoffrey A Block

1 reference

14 August 2017

Antonio Bellasi

1 reference

14 August 2017

Laura Kooienga

series ordinal

1 reference

14 August 2017

publication date

1 July 2006

1 reference

Hemodialysis International

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

225-234

1 reference

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Phosphate kinetics during hemodialysis: Evidence for biphasic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Aluminium and bone disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Progressive accumulation of lanthanum in the liver of normal and uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Determinants of progressive vascular calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Arterial calcifications and bone histomorphometry in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Modeling the implications of changes in vascular calcification in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

The evaluation of novel mixed metal hydroxy-carbonates as phosphate binders: an in-vivo study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Different Mg to Fe ratios in the mixed metal MgFe hydroxy-carbonate compounds and the effect on phosphate binding compared with established phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1542-4758.2006.00100.X

10.1111/J.1542-4758.2006.00100.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference